Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8777033 | 0.92 | CYP3A4 (0.71) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL8777031 | 0.91 | CYP3A4 (0.69) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL13081239 | 0.87 | CYP3A4 (0.66) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL8777049 | 0.83 | LMNA (0.72) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL8777025 | 0.82 | KMT2A (0.55) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL7886525 | 0.82 | RAB9A (0.57) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL8777023 | 0.79 | TNF (0.56) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL24715918 | 0.78 | KMT2A (0.50) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL17721716 | 0.78 | KMT2A (0.50) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL9633218 | 0.77 | RAB9A (0.59) | KMT2ACYP3A4CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019164891-A9 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-3313818-A1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | Celgene Corporation (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210262-A1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | CELGENE CORPORATION (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-3077548-A2 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | Celgene Corporation (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-3077547-A2 | METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES | Celgene Corporation (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015085160-A2 | METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES | CELGENE CORPORATION (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015085172-A2 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-2867671-A2 | METHODS FOR DETERMINING DRUG EFFICACY USING CEREBLON-ASSOCIATED PROTEINS | Celgene Corporation (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2699909-A1 | BIOMARKERS FOR THE TREATMENT OF MULTIPLE MYELOMA | Celgene Corporation (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2014028445-A2 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORPORATION (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014004990-A2 | METHODS FOR DETERMINING DRUG EFFICACY USING CEREBLON-ASSOCIATED PROTEINS | CELGENE CORPORATION (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2521543-A1 | A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ OR A DERIVATIVE THEREOF FOR TREATING CANCER | Celgene Corporation (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2012145309-A1 | BIOMARKERS FOR THE TREATMENT OF MULTIPLE MYELOMA | CELGENE CORPORATION (US) | 2012-10-26 | — | — | WO | disclosed |
| EP-2411506-A1 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS | Anthrogenesis Corporation (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011084968-A1 | A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ OR A DERIVATIVE THEREOF FOR TREATING CANCER | CELGENE CORPORATION (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-2235535-A2 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010111631-A1 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS | ANTHROGENESIS CORPORATION (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009105256-A2 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CELGENE CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009085262-A1 | METHOD OF TREATING CANCER WITH IMMUNOMODULATORY COMPOUNDS AND IGG | CELGENE CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009075797-A2 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |